Lexeo Therapeutics (NASDAQ:LXEO) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $17.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, December 10th. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Raymond James Financial started coverage on Lexeo Therapeutics in a research report on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 target price on the stock. Guggenheim started coverage on Lexeo Therapeutics in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Finally, Leerink Partners increased their target price on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.00.

Lexeo Therapeutics Stock Down 8.5%

LXEO stock opened at $7.43 on Tuesday. The company’s 50-day moving average price is $9.46 and its two-hundred day moving average price is $7.12. The firm has a market cap of $542.32 million, a P/E ratio of -2.75 and a beta of 1.75. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.15. Equities analysts predict that Lexeo Therapeutics will post -3.14 EPS for the current year.

Insider Activity

In related news, insider Tai Sandi See sold 3,888 shares of the firm’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $34,758.72. Following the completion of the transaction, the insider owned 65,862 shares in the company, valued at $588,806.28. This trade represents a 5.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Adler sold 3,382 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $30,235.08. Following the sale, the insider directly owned 73,261 shares in the company, valued at $654,953.34. The trade was a 4.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 24,646 shares of company stock valued at $221,037. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

Several large investors have recently modified their holdings of the business. AQR Capital Management LLC lifted its holdings in shares of Lexeo Therapeutics by 370.0% during the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after purchasing an additional 39,627 shares during the period. Millennium Management LLC raised its position in Lexeo Therapeutics by 654.8% during the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after purchasing an additional 929,538 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Lexeo Therapeutics during the 1st quarter worth about $85,000. Rhumbline Advisers lifted its holdings in Lexeo Therapeutics by 19.8% during the 1st quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after buying an additional 4,995 shares during the period. Finally, Palumbo Wealth Management LLC bought a new stake in shares of Lexeo Therapeutics in the 2nd quarter valued at about $226,000. Institutional investors own 60.67% of the company’s stock.

Key Lexeo Therapeutics News

Here are the key news stories impacting Lexeo Therapeutics this week:

• Positive Sentiment: Positive interim HEROIC‑PKP2 Phase I/II data: LX2020 showed dose‑dependent PKP2 protein increases (mean +93% low dose, +162% high dose), evidence of transduction in cardiac biopsies, and arrhythmia stabilization/improvement in most participants—company calls safety profile generally tolerable and plans further regulatory engagement. Read More.
• Positive Sentiment: Analyst support: Chardan reaffirmed a Buy and $17 price target (suggesting sizable upside from current levels); several other firms maintain Buy/Outperform ratings and multi‑dollar price targets, underpinning longer‑term optimism. Read More.
• Positive Sentiment: Company engagement and roadmap: Lexeo completed enrollment in HEROIC‑PKP2, will host a corporate webcast and expects 12‑month high‑dose data in Q4 2026—clear milestones that could re‑rate the stock if later data confirm benefit. Read More.
• Neutral Sentiment: Trading pause occurred (LULD pause) during the session—temporary market mechanism, not company action; webcast and archived materials were made available for investors. (Company filings/webcast)
• Negative Sentiment: Shares sold off after the update despite positive topline signals—some investors appear to be taking profits or pricing in safety/efficacy uncertainty. Read More. | Read More.
• Negative Sentiment: Safety and sample‑size concerns: five high‑dose participants had LFT elevations (managed per protocol) and one Grade‑3 sustained VT occurred and was deemed possibly treatment‑related—these issues and the small (n=10) dataset raise near‑term uncertainty. Read More.
• Negative Sentiment: Heavy short interest and insider selling: December short interest rose to ~10.83M shares (~15.7% of shares), and recent insider sales have been reported—both increase downside pressure if sentiment flips. (Market short‑interest and insider activity data)
• Negative Sentiment: Limited data set: interim results cover only 10 dosed participants with only a subset having 6+ months follow‑up—investors may wait for larger/longer data before committing. Read More.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.